Neuren Pharmaceuticals Limited (ASX:NEU)

Market Cap	1.54B
Revenue (ttm)	216.83M
Net Income (ttm)	142.04M
Shares Out	125.16M
EPS (ttm)	1.09
PE Ratio	11.35
Forward PE	93.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	577,169
Average Volume	701,203
Open	12.48
Previous Close	12.33
Day's Range	12.44 - 13.33
52-Week Range	8.61 - 24.00
Beta	1.66
RSI	60.95
Earnings Date	May 30, 2025

About Neuren Pharmaceuticals

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 8
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NEU

Financial Performance

In 2024, Neuren Pharmaceuticals's revenue was 216.83 million, a decrease of -6.51% compared to the previous year's 231.94 million. Earnings were 142.04 million, a decrease of -9.57%.